ALLURION TECHNOLOGIES INC Stock Price, News & Analysis

Allurion Technologies (NYSE: ALUR) has announced the submission of its final Pre-Market Approval (PMA) module to the FDA, along with additional analyses from its AUDACITY Study for its weight loss balloon device. The pivotal study has successfully met both co-primary endpoints after new analyses.

The study involved 550 subjects randomized 1:1 between treatment and control groups. Using updated imputation methods, the treatment group showed a 4.34% mean difference in weight loss at 48 weeks with a 3.14% super-superiority margin (p = .0142), exceeding the pre-specified 3% margin. At 40 weeks, the difference was even more pronounced at 4.90% with a 3.75% margin (p = .0006).

Allurion Technologies (NYSE: ALUR) presented two significant studies at ASMBS 2025 Annual Meeting showcasing the effectiveness of their AI-powered weight loss program. The first study of 19,946 patients demonstrated a 12.4% average total body weight reduction at four months, with increased muscle mass (6.5%) and lean body mass (6%), while reducing fat mass by 11.3% and visceral fat by 12.3%. The second study tracked 223 patients over four years, showing sustained weight loss maintenance of 89%, with patients maintaining 10.1% total body weight reduction after four years compared to 11.4% at four months. The Allurion Program combines a procedure-less gastric balloon with AI-powered behavior change support, remote monitoring, and digital tools to achieve metabolically healthy weight loss without surgery or anesthesia.

Allurion Technologies (NYSE: ALUR), a company focused on metabolically healthy weight loss, announced that its Founder and CEO, Dr. Shantanu Gaur, will deliver a presentation at the Jefferies Global Healthcare Conference in New York. The presentation is scheduled for June 4 at 3:45 p.m. ET. Interested parties can access the webcast through the Events & Presentations section of Allurion's investor relations website.

Allurion Technologies (NYSE: ALUR) presented significant clinical results at the SOFFCO.MM meeting in France, showcasing the effectiveness of their Allurion Program for weight loss. The study of 1,962 French patients demonstrated remarkable outcomes after four months:

- 12.2% average reduction in total body weight
- 6.6% increase in muscle mass percentage
- 11% decrease in fat mass
- 12.2% reduction in visceral fat index

Additionally, the company announced the resumption of shipments to France, with patient treatments expected to restart next month, marking their return to the French market with a focus on metabolically healthy weight loss.

Allurion Technologies (NYSE: ALUR) reported its Q1 2025 financial results, showing a revenue of $5.6 million, down from $9.4 million in Q1 2024. The company maintained its 2025 revenue guidance of $30 million while achieving significant cost reductions. Key highlights include: - Gross margin improved to 75% from 73% year-over-year - Operating expenses decreased by 37% to $11.4 million - Net operating loss reduced by 36% to $7.3 million - Cash balance of $20.4 million as of March 31, 2025 The company is progressing with its FDA approval process, having completed its Pre-PMA meeting and planning to submit the final PMA module by June. Allurion is also preparing to launch a trial combining its program with low-dose GLP-1 medications, aiming to maintain muscle mass and increase medication adherence.

Allurion Technologies (NYSE: ALUR) presented four groundbreaking studies at the European Congress on Obesity showcasing the effectiveness of their Allurion Program, which combines their swallowable intragastric balloon with an AI-powered Virtual Care Suite. Key findings include:

- Patients using GLP-1s with the Virtual Care Suite showed a 6.1% increase in lean body mass and 6.4% increase in muscle mass

- Combination therapy of Allurion Balloon with semaglutide achieved 21.2% body weight reduction, comparable to bariatric surgery outcomes

- The Allurion Program without GLP-1s demonstrated 12.4% weight reduction and 9.8% muscle mass increase in 2,000 patients

The studies suggest that Allurion's AI-driven behavioral support may help maintain muscle mass during GLP-1 therapy, while combination treatments could offer alternatives to bariatric surgery for severe obesity cases.

Allurion Technologies (NYSE: ALUR), a company focused on obesity treatment, has scheduled its first quarter 2025 financial results announcement for May 14, 2025. The company will host a conference call and webcast at 8:30 AM ET on the same day to discuss the results and provide a business update.

Participants can join via phone by dialing (888) 330-3417 (domestic) or +1 646 960 0804 (international) using Conference ID 1905455. The webcast will be available in the Events section of Allurion's Investor Relations website. A replay will be accessible by phone at (800) 770-2030 using Access Code 1905455, and the archived webcast will remain available on the company's website.

Allurion Technologies (NYSE: ALUR) has announced the postponement of its Special Meeting of Stockholders from April 4, 2025, to Thursday, April 10, 2025, at 12:00 p.m. (Eastern Time). The virtual meeting will be held via live audio webcast.

The postponement aims to allow additional time for proxy solicitation and provide stockholders more time to vote. The record date remains unchanged at March 14, 2025. Previously cast votes will remain valid unless stockholders choose to change or revoke them.

The Company's Board of Directors unanimously recommends voting FOR the proposals outlined in the Definitive Proxy Statement filed on March 24, 2025. Stockholders can access detailed information and voting instructions through the SEC website or Allurion's investor relations page.

Allurion Technologies (NYSE: ALUR) reported its Q4 and full-year 2024 financial results. Q4 revenue was $5.6 million with full-year revenue reaching $32.1 million. The company faced challenges with Q4 gross profit at $2.5 million (45% margin), down from $6.4 million (78% margin) in Q4 2023.

Key developments include:

• Resumed sales in France on February 12, 2025
• Positive topline results from AUDACITY FDA trial
• Initial data showing promising results combining Allurion Program with low-dose GLP-1s
• Launch of next-generation Allurion Balloon with smaller capsule size

The company reduced Q4 2024 operating expenses by 39% year-over-year to $19.6 million, including $3.8 million in restructuring charges. For 2025, Allurion projects revenue of approximately $30 million and plans to cut operating expenses by roughly 50% compared to 2024.